Evidence map›Paper›PMID 37986934›Full record

ArticlebioRxiv : the preprint server for biology2023

Loss of function of

Matthew Pierpoint, Warren Floyd, Amy J Wisdom, Lixia Luo, Yan Ma, Matthew S Waitkus, David G Kirsch

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Matthew PierpointDuke of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-6171-7086
Warren FloydDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amy J WisdomHarvard Radiation Oncology Program, Harvard University, Boston, MA, 02115, USA.
Lixia LuoDuke Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Yan MaDuke Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Matthew S WaitkusDuke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA.
David G KirschRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Duke Medical Center · USDuke University · USHarvard University · USPrincess Margaret Cancer Centre · CAThe University of Texas MD Anderson Cancer Center · USUniversity of Toronto · CA

Funding

Advancing Cancer Therapy through Ground Breaking Research in Radiation BiologyR35CA197616 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI David Guy Kirsch · 2016 to 2026
$10.7M
NCI NIH HHS R35 CA197616
6 · The paper itself

Abstract

The development of a telomere maintenance mechanism is essential for immortalization in human cancer. While most cancers elongate their telomeres by expression of telomerase, 10-15% of human cancers use a pathway known as alternative lengthening of telomeres (ALT). In this work, we developed a genetically engineered primary mouse model of sarcoma in CAST/EiJ mice which displays multiple molecular features of ALT activation after CRISPR/Cas9 introduction of oncogenic

Identifiers

PMID37986934
PMCPMC10659347
OpenAlexW4388460745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.